|1.||Trapella, Claudio: 1 article (12/2008)|
|2.||Marti, Matteo: 1 article (12/2008)|
|3.||Morari, Michele: 1 article (12/2008)|
12/01/2008 - "Trap-101 alleviated akinesia/bradykinesia and improved overall gait ability in hemiparkinsonian rats, being effective starting at 1 mg/Kg and without worsening motor deficit at 30 mg/Kg. To investigate the circuitry involved in the Trap-101 action, behavioral tests were performed in rats undergoing microdialysis. "
|2.||Parkinsonian Disorders (Parkinsonism)
12/01/2008 - "These data show that Trap-101 is an effective NOP receptor antagonist in vivo and confirm that NOP receptor antagonists alleviate parkinsonism through blockade of nigral NOP receptors and impairment of nigro-thalamic transmission."
12/01/2008 - "The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA."
|1.||Levodopa (L Dopa)